Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus Bevacizumab in Recurrent Glioblastoma with Nivolumab ± Ipilimumab Safety Cohorts
2013-003738-34Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in glioblastoma (GBM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2013-003738-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003738-34.